Skip to main content
. 2019 Oct 23;14(10):e0223520. doi: 10.1371/journal.pone.0223520

Table 2. A table to summarize the number of samples for each type of cancer used in each comparison.

DISEASE NT1 PT2 sITH3 gITH4 STAGE5 SURVIVAL6 PAM507
BRCA 112 1,093 1,093 1,020 1,002 325 473
KIPAN 129 889 889 659 632 287 0
GBMLGG 5 669 669 643 0 274 0
STES 46 599 599 558 142 71 0
HNSC 44 520 520 485 422 238 0
LUAD 59 515 515 489 487 211 0
LUSC 51 501 501 465 464 245 0
THCA 59 501 501 446 0 0 0
PRAD 52 497 497 469 0 0 0
BLCA 19 408 408 397 395 210 0
COADREAD 51 379 379 351 257 91 0
LIHC 50 371 371 354 333 155 0
CESC 3 304 304 291 0 99 0
SARC 2 259 259 242 0 0 0
PCPG 3 179 179 160 0 0 0
PAAD 4 178 178 158 66 43 0
UCEC 24 176 176 170 0 0 0
THYM 2 120 120 103 0 0 0
SKCM 1 103 103 103 0 0 0
CHOL 9 36 36 36 36 19 0
OV 0 303 0 0 0 0 0
LAML 0 173 0 0 0 0 0
TGCT 0 150 0 0 0 0 0
MESO 0 87 0 0 0 0 0
UVM 0 80 0 0 0 0 0
ACC 0 79 0 0 0 0 0
UCS 0 57 0 0 0 0 0
DLBC 0 48 0 0 0 0 0
SUM 725(20) 9,274(28) 8,297(20) 7,599(20) 4,236(11) 2,268(13) 473(1)

1 The NT column represents the number of normal tissue samples for each type of cancer.

2 The PT column represents the number of primary tumor RNA-seq samples per cancer type.

3 The sITH column represents the number of samples for which sITH can be calculated.

4 The gITH column represents the number of samples for which both sITH and gITH can be calculated.

5 The STAGE column shows the number of samples with cancer stage information among the samples for which sITH and gITH can be calculated.

6 The SURVIVAL column represents the number of samples with survival outcome information among the samples for which sITH and gITH can be calculated.

7 The PAM50 column shows the number of breast cancer samples with PAM50 label information among the samples for which sITH and gITH can be calculated.